

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/278607 A1

(51) International Patent Classification:
C12N 15/113 (2010.01) A61K 31/7125 (2006.01)
A61P 25/16 (2006.01)

(21) International Application Number:
PCT/US2022/035561

(22) International Filing Date:
29 June 2022 (29.06.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/216,119 29 June 2021 (29.06.2021) US
63/353,953 21 June 2022 (21.06.2022) US

(71) Applicant: **ALNYLAM PHARMACEUTICALS, INC.**
[US/US]; 675 West Kendall Street, Henri A. Tameer
Square, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **DANG, Lan Thi Hoang**; c/o Alnylam Phar-
maceuticals, INC., 675 West Kendall Street, Henri A.
Tameer Square, Cambridge, Massachusetts 02142 (US).
MCININCH, James D.; c/o Alnylam Pharmaceuticals,
INC., 675 West Kendall Street, Henri A. Tameer Square,
Cambridge, Massachusetts 02142 (US). **SCHLEGEL,
Mark K.**; c/o Alnylam Pharmaceuticals, INC., 675 West
Kendall Street, Henri A. Tameer Square, Cambridge, Mass-
achusetts 02142 (US). **CASTORENO, Adam**; c/o Alny-
lam Pharmaceuticals, INC., 675 West Kendall Street, Hen-
ri A. Tameer Square, Cambridge, Massachusetts 02142
(US). **NGUYEN, Tuyen M.**; c/o Alnylam Pharmaceuti-
cals, INC., 675 West Kendall Street, Henri A. Tameer
Square, Cambridge, Massachusetts 02142 (US). **BARRY,
Joseph**; c/o Alnylam Pharmaceuticals, INC., 675 West
Kendall Street, Henri A. Tameer Square, Cambridge, Mass-
achusetts 02142 (US). **STRICOS, Matthew**; c/o Alnylam
Pharmaceuticals, INC., 675 West Kendall Street, Henri A.
Tameer Square, Cambridge, Massachusetts 02142 (US).
LEBLANC, Sarah; c/o Alnylam Pharmaceuticals, INC.,
675 West Kendall Street, Henri A. Tameer Square, Cam-
bridge, Massachusetts 02142 (US).

(74) Agent: **MEIGS, Julie Broadus** et al.; PO Box 570489, At-
lanta, Georgia 30357-0037 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,

MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: LEUCINE-RICH REPEAT KINASE 2 (LRRK2) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF

(57) Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a leucine-rich repeat kinase 2 (LRRK2) gene, as well as methods of inhibiting expression of a LRRK2 gene and methods of treating subjects having a LRRK2-associated disease or disorder, e.g., Parkinson's disease, using such dsRNAi agents and compositions.

WO 2023/278607 A1